Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades

Analysts at Piper Jaffray downgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) from Neutral to Underweight. The target price for Sarepta Therapeutics has been lowered from $15 to $6. Sarepta Therapeutics shares fell 47.49 percent to $7.85 in pre-market trading.

Bank of America downgraded Canadian National Railway (USA) (NYSE: CNI) from Buy to Underperform. Canadian National Railway shares closed at $65.18 on Monday.

Analysts at Deutsche Bank downgraded U.S. Bancorp (NYSE: USB) from Buy to Hold. US Bancorp shares closed at $43.05 on Monday.

Evercore ISI Group downgraded Zions Bancorporation (NASDAQ: ZION) from Buy to Hold. Zions Bancorp shares dropped 2.57 percent to $26.59 in pre-market trading.

Analysts at Cantor Fitzgerald downgraded Whiting Petroleum Corp (NYSE: WLL) from Buy to Hold. Whiting Petroleum shares closed at $11.07 on Monday.

Latest Ratings for SRPT

Apr 2019Evercore ISI GroupInitiates Coverage OnOutperform
Mar 2019Morgan StanleyMaintainsOverweightOverweight
Mar 2019CitigroupMaintainsBuyBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (CNI + SRPT)

View Comments and Join the Discussion!

Latest Ratings

PEPMorgan StanleyReiterates137.0
AZRXH.C. WainwrightMaintains7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A Split Decision For This ETF's Holdings

Macquarie Initiates Splunk With Outperform Rating, $59 Price Target